BN Stock Analysis: Danone | PA
Packaged Foods | PA, France | Market Cap: 43.805m EUR | 12M Return: -1.6% | FR0000120644 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 90.4M
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Danone S.A. is a France-based multinational food and beverage company headquartered in Paris, operating across Europe, North America, Asia, Latin America, Africa, the Middle East, and the Commonwealth of Independent States. Founded in 1899 and formerly known as Groupe Danone, the company was renamed in April 2009. It is a constituent of the Consumer Staples sector and is classified in the Packaged Foods & Meats sub-industry, reflecting its positioning as a defensive consumer goods stock with exposure to essential, non-discretionary products.
The business is organized into three segments: Essential Dairy & Plant-Based, Specialized Nutrition, and Waters. Its product portfolio spans yogurts, dairy items, plant-based alternatives, ice creams, coffee drinks, and cheese under brands such as Activia, Actimel, Alpro, Danone, Oikos, YoPRO, Silk, and So Delicious. The Specialized Nutrition segment targets infants, children, and patients through formulas, complementary feeding, and medical nutrition (e.g., Aptamil, Nutricia, Nutrilon, Neocate, Fortimel), while the Waters segment markets natural mineral waters and flavored beverages including evian, Volvic, AQUA, Bonafont, and Mizone.
Danone distributes through retail chains, traditional outlets, convenience stores, hotels and restaurants, hospitals and pharmacies, and e-commerce platforms. The diversified, health-oriented portfolio - particularly the weighting toward dairy, plant-based, and medical nutrition - illustrates the companys focus on premium, wellness-driven categories, which have historically supported more stable margins and recurring demand relative to the broader packaged foods industry.
- China infant formula revenue pressured by declining birth rate
- Evian and Volvic bottled water volumes face demand headwinds
- Specialized Nutrition margins expand on premium product mix
| Net Income: 1.96b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -1.58 > 1.0 |
| NWC/Revenue: -1.98% < 20% (prev -2.63%; Δ 0.65% < -1%) |
| CFO/TA 0.07 > 3% & CFO 3.52b > Net Income 1.96b |
| Net Debt (9.99b) to EBITDA (4.39b): 2.28 < 3 |
| Current Ratio: 0.97 > 1.5 & < 3 |
| Outstanding Shares: last quarter (643.1m) vs 12m ago -0.05% < -2% |
| Gross Margin: 43.95% > 18% (prev 50.47%; Δ -6.53% > 0.5%) |
| Asset Turnover: 59.50% > 50% (prev 62.52%; Δ -3.02% > 0%) |
| Interest Coverage Ratio: 5.74 > 6 (EBIT TTM 3.14b / Interest Expense TTM 547.0m) |
| A: -0.01 (Total Current Assets 16.1b - Total Current Liabilities 16.6b) / Total Assets 48.6b |
| B: 0.38 (Retained Earnings 18.5b / Total Assets 48.6b) |
| C: 0.07 (EBIT TTM 3.14b / Avg Total Assets 46.2b) |
| D: 0.57 (Book Value of Equity 17.6b / Total Liabilities 30.9b) |
| Altman-Z'' = 2.22 = BBB |
| DSRI: 1.05 (Receivables 3.39b/3.22b, Revenue 27.5b/27.4b) |
| GMI: 1.15 (GM 50.47% / 43.95%) |
| AQI: 0.95 (AQ_t 0.54 / AQ_t-1 0.56) |
| SGI: 1.00 (Revenue 27.5b / 27.4b) |
| TATA: -0.03 (NI 1.96b - CFO 3.52b) / TA 48.6b) |
| Beneish M = -2.88 (Cap -4..+1) = A |
As of August 12, 2026, the stock is trading at EUR 67.30 with a total of 953,284 shares traded. Over the past week, the price has changed by -1.06%, over one month by -6.79%, over three months by +8.86% and over the past year by -1.63%.
Current recommended Stop Loss: 65.50 (which is 2.7% or 1.3 ATR below the current price).
Danone has no consensus analysts rating.
P/E Trailing = 22.5894
P/E Forward = 17.6678
P/S = 1.594
P/B = 2.4877
P/EG = 1.7161
Revenue TTM = 27.5b EUR
EBIT TTM = 3.14b EUR
EBITDA TTM = 4.39b EUR
Long Term Debt = 9.99b EUR (from longTermDebt, last quarter)
Short Term Debt = 6.50b EUR (from shortTermDebt, last quarter)
Debt = 18.3b EUR (from shortLongTermDebtTotal, last quarter) + Leases 902.0m
Net Debt = 9.99b EUR (calculated: Debt 18.3b - CCE 8.34b)
Enterprise Value = 53.8b EUR (43.8b + Debt 18.3b - CCE 8.34b)
Interest Coverage Ratio = 5.74 (Ebit TTM 3.14b / Interest Expense TTM 547.0m)
EV/FCF = 22.21x (Enterprise Value 53.8b / FCF TTM 2.42b)
FCF Yield = 4.50% (FCF TTM 2.42b / Enterprise Value 53.8b)
FCF Margin = 8.81% (FCF TTM 2.42b / Revenue TTM 27.5b)
Net Margin = 7.12% (Net Income TTM 1.96b / Revenue TTM 27.5b)
Gross Margin = 43.95% ((Revenue TTM 27.5b - Cost of Revenue TTM 15.4b) / Revenue TTM)
Gross Margin QoQ = 37.74% (prev 50.33%)
Tobins Q-Ratio = 1.11 (Enterprise Value 53.8b / Total Assets 48.6b)
Interest Expense / Debt = 2.98% (Interest Expense 547.0m / Debt 18.3b)
Taxrate = 28.48% (802.0m / 2.82b)
NOPAT = 2.24b (EBIT 3.14b * (1 - 28.48%))
Current Ratio = 0.97 (Total Current Assets 16.1b / Total Current Liabilities 16.6b)
Debt / Equity = 1.04 (Debt 18.3b / totalStockholderEquity, last quarter 17.6b)
Debt / EBITDA = 2.28 (Net Debt 9.99b / EBITDA 4.39b)
Debt / FCF = 4.12 (Net Debt 9.99b / FCF TTM 2.42b)
Total Stockholder Equity = 17.0b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.24% (Net Income 1.96b / Total Assets 48.6b)
RoE = 11.49% (Net Income TTM 1.96b / Total Stockholder Equity 17.0b)
RoCE = 11.61% (EBIT 3.14b / Capital Employed (Equity 17.0b + L.T.Debt 9.99b))
RoIC = 6.04% (NOPAT 2.24b / Invested Capital 37.2b)
WACC = 3.75% (E(43.8b)/V(62.1b) * Re(4.43%) + D(18.3b)/V(62.1b) * Rd(2.98%) * (1-Tc(0.28)))
Discount Rate = 4.43% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 58.30 | Cagr: 0.30%
[DCF] Terminal Value 73.10% ; FCFF base≈2.60b ; Y1≈2.28b ; Y5≈1.84b
[DCF] Fair Price = 30.51 (EV 29.6b - Net Debt 9.99b = Equity 19.6b / Shares 642.1m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 34.75 | EPS CAGR: 20.37% | SUE: N/A | # QB: 0
Revenue Correlation: -17.52 | Revenue CAGR: -0.10% | SUE: 1.11 | # QB: 1
EPS current Quarter (2026-03-31): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS next Quarter (2026-06-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-12-31): EPS=3.94 | Chg30d=+0.85% | Revisions=-12% | GrowthEPS=+3.6% | GrowthRev=+3.3%
EPS next Year (2027-12-31): EPS=4.23 | Chg30d=+0.23% | Revisions=+40% | GrowthEPS=+7.5% | GrowthRev=+4.6%
[Analyst] Revisions Ratio: +14% (up=15, down=11)